Co-variables influencing 5-fluorouracil clearance during continuous venous infusion. A NONMEM analysis

被引:67
作者
Etienne, MC
Chatelut, E
Pivot, X
Lavit, M
Pujol, A
Canal, P
Milano, G [1 ]
机构
[1] Ctr Antoine Lacassagne, Oncopharmacol Lab, F-06189 Nice 2, France
[2] Inst Claudius Regaud, Toulouse, France
关键词
5-fluorouracil; pharmacokinetics; NONMEM analysis;
D O I
10.1016/S0959-8049(97)00345-6
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The objective of this study was to attempt to identify patient co-variables which could influence interpatient variability in 5-fluorouracil (5-FU) clearance during a 5-day continuous venous infusion (CVI, cisplatin 100 mg/m(2) day 1 then 5-FU 1 g/m(2)/day days 2-6). The analysis was performed using a NONMEM program according to a linear one-compartment model. A total of 186 cycles (2 samples per day, 8 a.m. and 5 p.m.) were analysed from 104 patients with various cancers (the majority of head and neck and oesophagus). The study co-variables were age, sex, body surface area, hepatic metastases, peripheral mononuclear cell dihydropyrimidine dehydrogenase activity (PMNC-DPD), liver enzymes, clock-time (8 a.m. versus 5 p.m.), elapsed time during CVI. The data showed that 5-FU clearance was significantly reduced by increased age, low PMNC-DPD, high serum alkaline phosphatase and elapsed time during infusion. These data may be useful for improving knowledge of predictive factors which can influence 5-FU exposure and thus predispose to toxic manifestations. (C) 1998 Elsevier Science Ltd.
引用
收藏
页码:92 / 97
页数:6
相关论文
共 42 条
[1]  
AU JL, 1979, CANCER RES, V42, P4289
[2]  
Beal SL., 1992, NONMEM USERS GUIDE 6
[3]  
BEAL SL, 1985, DRUG FATE METABOLISM, V5, P135
[4]  
Boekmann AJ, 1992, NONMEM USERS GUIDE 5
[5]   CONTINUOUS 5-DAY REGIONAL CHEMOTHERAPY BY 5-FLUOROURACIL IN COLON-CARCINOMA - PHARMACOKINETIC EVALUATION [J].
BOUBLIL, JL ;
MILANO, G ;
KHATER, R ;
BOURRY, J ;
THYSS, A ;
BRUNETON, JN ;
RENEE, N ;
PHILIP, C ;
NAMER, M .
BRITISH JOURNAL OF CANCER, 1985, 52 (01) :15-20
[6]  
BREIMER DD, 1983, INT J CLIN PHARM RES, V3, P399
[7]   CARBOPLATIN DOSAGE - PROSPECTIVE EVALUATION OF A SIMPLE FORMULA BASED ON RENAL-FUNCTION [J].
CALVERT, AH ;
NEWELL, DR ;
GUMBRELL, LA ;
OREILLY, S ;
BURNELL, M ;
BOXALL, FE ;
SIDDIK, ZH ;
JUDSON, IR ;
GORE, ME ;
WILTSHAW, E .
JOURNAL OF CLINICAL ONCOLOGY, 1989, 7 (11) :1748-1756
[8]   PREDICTION OF CARBOPLATIN CLEARANCE FROM STANDARD MORPHOLOGICAL AND BIOLOGICAL PATIENT CHARACTERISTICS [J].
CHATELUT, E ;
CANAL, P ;
BRUNNER, V ;
CHEVREAU, C ;
PUJOL, A ;
BONEU, A ;
ROCHE, H ;
HOUIN, G ;
BUGAT, R .
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1995, 87 (08) :573-580
[9]  
Chazal M, 1996, CLIN CANCER RES, V2, P507
[10]  
COUDERT B, 1995, EUR J CANC S5, V31, P201